A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy
Project objectives
Phase II randomized trial involving the administration of Pembrolizumab (MK3475) as maintenance therapy in non-operable patients with non-small cell lung cancer (NSCLC) who performed a definitive chemo-radiant treatment. The purpose of this study is to evaluate whether in patients with non-small cell lung cancer (NSCLC) in stage III not eligible for surgical resection who have achieved a disease response or stability following chemo-radiant treatment, the treatment with Pembrolizumab in maintenance (24 months) is able to prolong disease-free survival compared with clinical observation alone.
Start/End Date
no enrolled patients, CE approval January 2018
Project manager
Prof. Ramella
Coordinator of the project
University of Turin
Sources of financing
No-profit
